Bilateral low frequency rTMS of the primary motor cortex may not be a suitable treatment for levodopa-induced dyskinesias in late stage Parkinson's disease
- PMID: 26777410
- DOI: 10.1016/j.parkreldis.2015.11.009
Bilateral low frequency rTMS of the primary motor cortex may not be a suitable treatment for levodopa-induced dyskinesias in late stage Parkinson's disease
Abstract
Background: In late stage Parkinson patients there is an unmet need for new treatments to adequately control motor complications, especially dyskinesias. In several preliminary studies, it has been suggested that applying unilateral low-frequency repetitive transcranial magnetic stimulation (LF rTMS), delivered at the primary motor cortex (MC) or the supplementary motor area (SMA), may reduce levodopa-induced dyskinesias (LID), either in a single or a multiple session stimulation protocol. In our current clinical research, we examined whether single or multiple (accelerated) sham-controlled bilateral LF rTMS session(s) applied to the primary motor cortices are able to reduce levodopa-induced dyskinesias in patients with advanced Parkinson's disease.
Methods: During a levodopa challenge test, we first investigated the effect of a single sham-controlled session of LF rTMS (1 Hz) to both left and right primary motor cortical areas on dyskinesias and motor function in nine late-stage Parkinson patients. In a second study, patients were assigned to a five day sham-controlled bilateral motor cortex cross-over accelerated LF rTMS protocol and effects on dyskinesias, motor and executive function and emotional status were assessed.
Results: We found no significant clinical change in levodopa-induced dyskinesias and motor function with either stimulation protocol.
Conclusions: One or multiple bilateral LF rTMS session(s) applied to the primary motor cortex were unable to reduce levodopa-induced dyskinesias in late-stage Parkinson patients.
Similar articles
-
Low-frequency repetitive transcranial magnetic stimulation for dyskinesia and motor performance in Parkinson's disease.J Clin Neurosci. 2014 Aug;21(8):1373-6. doi: 10.1016/j.jocn.2013.11.025. Epub 2014 Mar 13. J Clin Neurosci. 2014. PMID: 24631324 Clinical Trial.
-
Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.Mov Disord. 2009 Jan 30;24(2):246-53. doi: 10.1002/mds.22348. Mov Disord. 2009. PMID: 18951540 Clinical Trial.
-
Low frequency rTMS of the SMA transiently ameliorates peak-dose LID in Parkinson's disease.Clin Neurophysiol. 2006 Sep;117(9):1917-21. doi: 10.1016/j.clinph.2006.03.033. Epub 2006 Aug 1. Clin Neurophysiol. 2006. PMID: 16887383 Clinical Trial.
-
rTMS effects on levodopa induced dyskinesias in Parkinson's disease patients: searching for effective cortical targets.Restor Neurol Neurosci. 2010;28(4):561-8. doi: 10.3233/RNN-2010-0556. Restor Neurol Neurosci. 2010. PMID: 20714078 Review.
-
Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.Eur Neurol. 2008;60(2):57-66. doi: 10.1159/000131893. Epub 2008 May 15. Eur Neurol. 2008. PMID: 18480609 Review.
Cited by
-
Repetitive Transcranial Magnetic Stimulation Alleviates MPTP-Induced Parkinson's Disease Symptoms by Regulating CaMKII-CREB-BMAL1 Pathway in Mice Model.Neuropsychiatr Dis Treat. 2024 Sep 11;20:1693-1710. doi: 10.2147/NDT.S465898. eCollection 2024. Neuropsychiatr Dis Treat. 2024. PMID: 39279880 Free PMC article.
-
Clinical neurophysiology in the treatment of movement disorders: IFCN handbook chapter.Clin Neurophysiol. 2024 Aug;164:57-99. doi: 10.1016/j.clinph.2024.05.007. Epub 2024 May 23. Clin Neurophysiol. 2024. PMID: 38852434 Review.
-
Design issues in crossover trials involving patients with Parkinson's disease.Front Neurol. 2023 Aug 21;14:1197281. doi: 10.3389/fneur.2023.1197281. eCollection 2023. Front Neurol. 2023. PMID: 37670777 Free PMC article.
-
Therapeutic Potential of Low-Intensity Magnetic Field Stimulation in 6-Hydroxydopamine Rat Model of Parkinson's Disease: From Inflammation to Motor Function.Ann Neurosci. 2023 Jan;30(1):11-19. doi: 10.1177/09727531221117634. Epub 2022 Aug 27. Ann Neurosci. 2023. PMID: 37313335 Free PMC article.
-
Comparative efficacy of transcranial magnetic stimulation on different targets in Parkinson's disease: A Bayesian network meta-analysis.Front Aging Neurosci. 2023 Jan 4;14:1073310. doi: 10.3389/fnagi.2022.1073310. eCollection 2022. Front Aging Neurosci. 2023. PMID: 36688161 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical